Histocell is a clinical-stage biopharmaceutical company, specialized in developing cell therapy medicaments and novel medical devices for regenerative medicine, with a therapeutic approach focus on the control of oxidative stress. We work to improve people’s quality of life by creating new Cell Therapy medicaments.
Our headquarters is located at the Bizkaia Science and Technology Park (Spain), with facilities comprising a 65 m2 GMP certified manufacturing room for cell therapy medicinal products, several laboratories for quality control and R&D activities and a 2000 m2 medical device manufacturing plant. Our team meets the maximum quality standards through GMP and ISO 9001/2000 certifications.
Company's pipeline includes medical devices for promotion of Natural Wound Healing (Reoxcare® , Vexoderm®), Dermatologic Tissue Regeneration (Histoessence®, Wharton Gel Complex®, Neofibrin®) as well as Cell Therapy programs based on adipose derived mesenchymal stem cells (AMSC) for Bone regeneration and based on HC016 cellular product (proprietary technology) for Acute Spinal Cord Injury and Lung disease.
Finally, Histocell, as an authorized ATMP manufacturing laboratory, offers Contract Manufacturing Services for both GMP and GMP-like manufacturing of cell therapy products.
Our headquarters is located at the Bizkaia Science and Technology Park (Spain), with facilities comprising a 65 m2 GMP certified manufacturing room for cell therapy medicinal products, several laboratories for quality control and R&D activities and a 2000 m2 medical device manufacturing plant. Our team meets the maximum quality standards through GMP and ISO 9001/2000 certifications.
Company's pipeline includes medical devices for promotion of Natural Wound Healing (Reoxcare® , Vexoderm®), Dermatologic Tissue Regeneration (Histoessence®, Wharton Gel Complex®, Neofibrin®) as well as Cell Therapy programs based on adipose derived mesenchymal stem cells (AMSC) for Bone regeneration and based on HC016 cellular product (proprietary technology) for Acute Spinal Cord Injury and Lung disease.
Finally, Histocell, as an authorized ATMP manufacturing laboratory, offers Contract Manufacturing Services for both GMP and GMP-like manufacturing of cell therapy products.
Location: Spain, Autonomous Community of the Basque Country, Derio
Employees: 11-50
Phone: +34 946 56 79 00
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | Orza Inves... | orza.info |
Mentions in press and media 4
| Date | Title | Description |
| 17.09.2018 | El fondo japonés Cell Innovation Partners entra en Histocell, participada por GCRPV y Seed Bizkaia, entre otros | 14/09/2018 EL FONDO JAPONÉS CELL INNOVATION PARTNERS ENTRA EN HISTOCELL, PARTICIPADA POR GCRPV Y SEED BIZKAIA, ENTRE OTROS. El fondo japonés de inversión Cell Innovation Partners ha entrado en el accionariado de Histocell, participada por... |
| 30.09.2016 | Histocell, participada por GCRPV y Seed Capital Bizkaia, amplía capital en €4M y da entrada a dos nuevos socios | 30/09/2016 HISTOCELL, PARTICIPADA POR GCRPV Y SEED CAPITAL BIZKAIA, AMPLÍA CAPITAL EN €4 MILLONES Y DA ENTRADA A DOS NUEVOS SOCIOS. Histocell, participada por las entidades de capital riesgo (venture capital) GCRPV y Seed Capital Bizkaia,... |
| 11.06.2015 | Histocell cierra el primer tramo de una ronda de €4M para la internacionalización de Reoxcare | 10/06/2015 HISTOCELL CIERRA EL PRIMER TRAMO DE UNA RONDA DE €4 MILLONES PARA LA INTERNACIONALIZACIÓN DE REOXCARE. Histocell, compañía especializada en medicina regenerativa y terapia celular, ha cerrado el primer tramo de la ronda de fina... |
| 19.01.2012 | Genoma España, a través de Innocash, aporta €450.000 a Histocell | 19/01/2012 Nota de prensa GENOMA ESPAÑA, A TRAVÉS DE INNOCASH, APORTA €450.000 A HISTOCELL. Histocell, el Hospital Clínic de Barcelona y el CSIC han cerrado un acuerdo de licencia por el cual la biotecnológica vasca compromete un mímino ... |